Member Info for Laura2022

More Management purchases

Out of 68mln shares there are 90% held by management or funds,the top 2 holders of 40% combined are mgmt too.

Shareholders

NameEquities%Valuation

Arron Tolley

22.86 % 

David Bunka

18.13 % 

 Gresham House Asset Management Ltd. (Investment Management)

5.685 % 

 Gresham House Asset Management Ltd.

5.168 % 

 Amati Global Investors Ltd.

4.548 % 

 Amati Global Investors Ltd. (Venture Capital)

4.320 % 

 Meneldor BV

0.4715 % 

Lynn Stevenson

0.2252 % 

Karen Tolley

0.0105 % 

Alan Tolley

0.0105 %

Shenner

That's the thoughts I also had re : APTA potentially following ITS and AAMTE

PM

Those who took 1p cannot sell until at least 22nd August

Please at least read the RNSs

This should be a steady recovery don't you think ?

I am adding more to funded pharmaceutical companies ...APTA and PYC

2.16p for 400,000 in final minutes

They will give you 2.1p for 400,000shsres

The Company believes it has a leading position in aptamer technology, a technology that the Company believes can make significant inroads into the annual c.$171 billion affinity ligand market. The business model aims to deliver both recurring fee-for-service revenue, and higher risk, higher value licensing revenue that could contribute significant incremental revenues through upfront, milestones and royalty payments

If it helps its 2.06p sell 2.45p buy

I do not think it will go to the placing price

It's over 2p to sell not 1.5p as it says here

Im now getting

£1000 2.5p

£1500 3p

Thanks herehope

Changed now to 2.55 to buy so I am adding

Very hard to buy on HL , is anyone else finding it hard ?

I can sell 145000 shares at 2.6p

Everything is pretty much a buy ranging from 2.17p to 2.4p+

Many thanks Neil

Some are saying APRA may have been shorted for 12mths.....can this happen?

Aptamer's model will remain to use its contract research relationships as a platform to build lower-risk fee-for-service revenues and horizon scan for material licence fee opportunities. Under the revised strategy, the Company's focus will be on developing the core fee-for-service revenues to achieve profitability. The Company has already announced signing four contracts with a combined value of up to £507,000 for the current financial year (subject to ongoing commercial and scientific attrition), which form part of a current rolling pipeline of £2.2 million (which is risk adjusted for commercial and scientific attrition) across 30 discrete projects.

Aptamer will continue to target opportunities to licence its technology to the developers of diagnostic tests and therapeutics. If successful, these opportunities have the potential to generate material recurring revenue streams

The funds can't be admitted till 21st August

Some on Telegram saying short squeeze APTA like ITS

Good to see this RNS

Going well from 10pence

Someone on Telegram saying the reason ITS rose was due a short squeeze , what does this mean please ?

They are saying APTA only has 68mln shares and there might be kne here as the shares don't exist ?

I don't understand?